Posted by AGORACOM
at 12:08 PM on Monday, May 31st, 2021
When it comes to small-cap companies, tech-focused Datametrex AI is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.
In our newest interview with Datametrex, we sit down with CEO Marshall Gunter to discuss the company’s record-breaking Q1 2021, their explosive AI business, their incredibly successful foray into the COVID-19 market, and more.
Record Q1 Revenue of $19.04 Million up 2,253%
Record Adjusted EBITDA of $10.68 Million up 1,548%
To say the partnership between Loop Insights and one of Canada’s largest telecommunications companies ($15.5 billion in annual revenue in 2020 and 16 million customer connections) was an understatement.
Posted by AGORACOM
at 5:16 PM on Thursday, May 13th, 2021
Whereas many companies are just now trying to capitalize on the opportunities presented in the current and massive future of PropTech, Universal PropTech Inc. is actually delivering healthy building solutions and services for developers, owners, and operators in Canada. They’ve also turned their attention towards the global COVID-19 diagnostics market size, which is estimated at USD$84.4 billion in 2020.
We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about the launch of ISBRG Corp’s SpotLight-19(C) clinical trial and new R&D funding, the global COVID-19 diagnostics market, their marketing/distribution plans for the future, and more. Check out the interview now.
Posted by AGORACOM-JC
at 5:53 PM on Tuesday, May 11th, 2021
Loop Insights (MTRX: TSXV) (RACMF: OTCQB) announced the signing of an LOI with All Net LLC to provide a custom technology stack that will power the All Net Resort and Arena Project.
What is the All Net Resort and Arena Project?
A new $USD 2.7 Billion entertainment venue in Las Vegas. A non-gaming, business and family-friendly destination that is situated in the heart of the strip and will include but is not limited to:
23,000 seat multi-purpose arena with a retractable roof
500-room 5 star, all suite luxury Spa Hotel
2,000-room hotel tower
250,000 sq. ft. convention center
350,000 sq. ft. food and retail plaza with exclusive retail shops
World-class restaurants and nightclubs
2,500-seat dinner show room
and more
At the core of the partnership will be Loop’s real-time AI data intelligence and digital wallet platform.
What did CEO Rob Anson have to say?
“The All Net Resort and Arena is going to be a truly revolutionary entertainment complex. The $2.7 billion project is situated on a 27-acre parcel just across from the Las Vegas Convention Center consisting of multiple world-class venues, the size and scope of which signals another big win for Loop in the sports and entertainment venue capital of the world. Partnering from the ground up means Loop will provide digital innovations and truly personalized visitor experiences that are second to none.”
The proposed partnership will strengthen Loop’s leadership position in the Venue Management, Data Analytics and Customer & Fan Engagement areas. The deal is expected to formalize before the end of June.
Sit back, relax and watch this powerful interview with Loop Insights CEO Rob Anson.
Posted by AGORACOM-JC
at 7:12 PM on Friday, April 30th, 2021
When it comes to small-cap companies, tech-focused Datametrex AI is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.
Financial Highlights for year ending December 31, 2020:
Revenue of $12.3M vs. $3.4M for FY 2019
An increase of 264%
We sat down with CEO Marshall Gunter to discuss these highlights, the COVID-19 landscape, telemedicine, 2021 plans, and more.
Posted by AGORACOM-JC
at 6:21 PM on Thursday, April 29th, 2021
What do you get when you combine the leading provider of artificial intelligence driven real-time data insights for brick and mortar retailers, with the global leader in consumer data analytics operating in 100 markets and covering 90% of the world’s population?
Earlier today Loop Insights $MTRX $RACMF and NielsenIQ made this joint announcement that can be summarized by the following excerpt:
“NielsenIQ’s market leading fast-moving consumer goods coverage and Loop’s transformative artificial intelligence solutions present opportunities for collaboration and business development across channels. Retailers will benefit from an enhanced understanding of consumer behavior, thereby boosting personalization, targeting and activation initiatives through the joint power of NielsenIQ and Loop.”
More than just lip service, NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a ground-breaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables decision-making for the world’s leading consumer goods companies and retailers. In short, NielsenIQ measures every consumer transaction to deliver the knowledge that every business needs to drive growth.
If you thought that was powerful, the combination of Loop Insights means that knowledge will be delivered in real-time, something NielsenIQ VP Richard Lee says doesn’t exist in the market today.
How big is this alliance to $MTRX? This quote from CEO Rob Anson says it all:
“The scope, gravity and validation of this agreement with NielsenIQ represent an incredible milestone for Loop and its shareholders. NielsenIQ is the global leader when it comes to measurement and data analytics, as well as providing the most complete and trusted view of the market for leading CPG brands and retailers. In establishing this alliance, Loop is now on a path to achieve global enterprise scale, and has firmly put a stake in the ground as an emerging disruptive player in the world of retail data aggregation and analytics.”
Watch this powerful interview with NielsenIQ VP of Strategic Alliances, Richard Lee and Loop Insights CEO, Rob Anson to learn how they plan to transform the retail sector.
Posted by AGORACOM
at 8:21 AM on Wednesday, April 21st, 2021
XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that it has entered into an agreement (the “Agreement”) with an established German pharmaceutical wholesaler and service provider (the “Distributor”) for the distribution, storage and logistics of XPhyto’s diagnostic products in Germany. The Agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab is registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
Pursuant to the Agreement, the Distributor will distribute, store and deliver Covid-ID Lab test kits according to the product specifications and all applicable regulations to XPhyto’s customers. In addition, the Distributor will provide the documentation and fulfillment of storage obligations, the fulfillment of reporting and notification obligations, and the processing of any returned products. The obligations and services to be rendered under the Agreement satisfy all of the logistical and regulatory requirements for the commercial sale of COVID-ID Lab in Germany.
“With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of COVID-ID Lab,” said Hugh Rogers, CEO and Director of XPhyto. “The Company’s commercialization strategy is focused on the German market for initial product launch and the creation of robust and sustainable sales.”
Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.
XPhyto is currently in discussions with various potential customers, distribution and wholesale partners as well as potential licensees. The sales launch in Europe is targeted for April 2021. The Company will provide further information and updates in due course.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
Posted by AGORACOM
at 8:12 AM on Tuesday, April 20th, 2021
Mr. Wolfgang Probst appointed as the Chief Operations Officer (COO) of XPhyto
Addition of Mr. Manfred Buchberger as the Head of Corporate Development
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the Head of Corporate Development at XP Diagnostics GmbH (“XP Diagnostics”), a wholly owned German subsidiary of the Company. With European CE-IVD approval announced March 18, 2021, for the Company’s lead diagnostic product, Covid-ID Lab, XPhyto continues to enhance its commercial team as it anticipates near-term distribution and sales.
Mr. Probst is an experienced management and finance consultant with expertise in mergers and acquisitions, corporate re-organizations, and divestitures. He has a proven track record of leadership, strategic planning, and organizational restructuring having guided multiple startups from inception to financial success. Mr. Probst was responsible for successfully structuring XPhyto’s European operations and establishing associated partnerships and collaborations, both commercial and academic. As the newly appointed COO of XPhyto, Mr. Probst will be responsible for managing the Company’s global operations. Mr. Probst will remain a director of XPhyto and the managing director of XP Diagnostics.
Mr. Buchberger is a global leader in the medical diagnostics industry. For almost a decade, he was the CEO and a member of the Global Management Board of a major European medical diagnostics and analytics company with annual revenues of over 600 million Euro. His addition to the Company brings decades of diagnostics industry experience focused on international business development, sales, marketing, and product management. Mr. Buchberger has successfully created, implemented, and managed business growth strategies across Europe, North and South America, Middle East and Asia, including the successful launch of new medical diagnostic products.
On March 18, 2021, XPhyto announced European commercial approval of Covid-ID Lab, a rapid 25-minute point-of-care PCR test for COVID-19. Mr. Probst and Mr. Buchberger will be responsible for executing the global product launch and businesses development of Covid-ID Lab.
Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.
